Skip to main content

VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference

Written by Customer Service on . Posted in Public Companies.

BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Iain Stuart, Ph.D., Chief Scientific Officer of VYNE, will be presenting at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference (in-person) on July 27, 2022.

B&T Cell-Mediated Autoimmune Disease Drug Development Conference (in-person) – Presentation Details
  
Presentation Date:July 27, 2022
  
Presenter:Iain Stuart, Ph.D., Chief Scientific Officer of VYNE
  
Presentation Track:Harnessing Autoantibody Signatures and Mapping Out the B&T Cell-Mediated
Autoimmune Disease Landscape
  
Presentation Title:The InhiBET™ Platform: Bromodomain and End Terminal (BET) Inhibitors 
in Autoimmune Disease

Slides will be accessible on the “Events and Presentation” section of the VYNE website at https://vynetherapeutics.com/investors-media/events_presentations/

About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary pipeline includes FMX114 for the potential treatment of mild-to-moderate atopic dermatitis, and access to a library of bromodomain & extra-terminal (BET) domain inhibitors licensed from In4Derm Limited. The BET inhibitor platform includes lead programs VYN201 (pan-BETi) and VYN202 (selective-BETi) and access to a library of (BET) domain inhibitors for the potential treatment of immuno-inflammatory conditions.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com 

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.